Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. - Wikidata - awgldk - TriplyDB

Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy.

Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy.

http://www.wikidata.org/entity/Q37116373

about

The role of FLT3 in haematopoietic malignancies Cancer immunotherapy: moving beyond current vaccines T cell responses against tumor associated antigens and prognosis in colorectal cancer patients Diversity and recognition efficiency of T cell responses to cancer Adoptive T cell therapy: Addressing challenges in cancer immunotherapy T cell avidity and tumor recognition: implications and therapeutic strategies.Use of recombinant lentivirus pseudotyped with vesicular stomatitis virus glycoprotein G for efficient generation of human anti-cancer chimeric T cells by transduction of human peripheral blood lymphocytes in vitro.Prion diseases: immunotargets and therapy Dendritic cell-based cancer immunotherapy for colorectal cancer Peptide Vaccine Therapy in Colorectal Cancer Lung cancer vaccines Immunotherapy for colorectal cancer The emerging role of immunotherapy in colorectal cancer Immunotherapy in human colorectal cancer: Challenges and prospective Cancer immunotherapy via dendritic cells The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting Breast cancer vaccines: a clinical reality or fairy tale?Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients.Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines Colorectal cancer immunotherapy.The Cytokine Flt3-Ligand in Normal and Malignant Hematopoiesis Pilot study of sentinel-node-based adoptive immunotherapy in advanced colorectal cancer.Progress in cancer vaccines by enhanced self-presentation A broadly applicable approach to T cell epitope identification: application to improving tumor associated epitopes and identifying epitopes in complex pathogens.Innate immune regulation by STAT-mediated transcriptional mechanisms.Identification of novel human CTL epitopes and their agonist epitopes of mesothelin.Progress on new vaccine strategies for the immunotherapy and prevention of cancer.A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survival.Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials.Strategies for designing and optimizing new generation vaccines.Dendritic cell subsets in health and disease.Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review.Dendritic cell recovery post-lymphodepletion: a potential mechanism for anti-cancer adoptive T cell therapy and vaccination Heat-shock protein-based vaccines for cancer and infectious disease.A peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung cancer Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses.Major histocompatibility complex (MHC) tetramer technology: an evaluation.Enhancing antitumor immune responses: intracellular peptide delivery and identification of MHC class II-restricted tumor antigens.Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction.Prospects for immunotherapy of malignant disease.

P2860

Q24319174-18E46F18-9864-435F-8996-A4FF6B577ACD Q24548229-30BD578E-AF79-44B5-B6CF-86CEFC097E1C Q24796257-94F1E42B-C1AD-419D-ABB1-65A9C0F3742E Q24796652-06BC32AD-85FB-4379-94D7-2F8DD365F6AC Q24805804-FF31877F-2B72-4E1E-AC13-FA4D40E2B891 Q24815775-96151E22-8B4C-43B6-8C7C-249B9C927E10 Q25257888-733B60F9-2E68-43F7-8A8B-629E68DA7894 Q26741258-7218EE2D-3231-47C3-910A-0B69D06372BC Q26751339-4C0800E6-8AB0-47E3-BCB3-51C92165E335 Q26830336-82B5387D-2358-458B-AE1D-2D70E7C430B0 Q27014375-B79F2096-5693-4139-A93C-AD5BFC5C536E Q27021837-5F2B4455-AA18-43E6-8A84-D78DABED1855 Q28067898-45F4F77B-3DD6-4EE7-80AA-EF42B49C2173 Q28068788-EB3FB1EA-A136-407A-AE36-692CB0535549 Q29615444-CBBE4CAB-E41E-4A98-BAED-EA559906F86E Q29618424-0930939B-7CE5-46E7-BDDA-973EFC4B0B12 Q30351838-B4950864-A24C-4CF9-BAB4-94770FA2DB47 Q31157425-3FD57CFD-2660-49D9-B3DA-A85E7ACB062A Q33255244-7255A4BC-D70E-4A07-88AC-366F5909B82C Q33701465-CAAECA8E-FB72-4D2C-B4E6-8C84014EC4F0 Q33838356-570067BA-C476-475C-A876-63EC40309E2F Q33928210-B54E25C5-C8E4-4E1A-A8FE-B6045CE05323 Q33929076-2E5116C6-C4F3-4EBB-B80B-FB54EF6773EF Q34004266-F6F778A7-BEE8-4FDF-B7F8-11BA613C2B62 Q34055968-F889FA5C-46CB-47DC-838E-D37DDF89D270 Q34313298-E4689185-CA25-45E9-8A9D-0F5BFE3D1448 Q34328457-37FC2F47-38D7-4A55-9FEE-624DD56E13DE Q34365990-C21D8F71-A0D5-4064-B791-9D22C418169E Q34434814-810A8166-49DC-4359-BEE9-3F03886C758F Q34572198-B40A49D7-8CC3-44D1-AEF2-301FED4A3052 Q34582889-B68E5F3C-D6B6-4698-835A-4854DDDFCB90 Q34585684-B9F3B818-FBB0-4A82-B4E8-09EF2DE60CE5 Q34759603-82DD9316-14A7-4DD0-B879-F9B490DC60E3 Q34768299-698CB957-F3F6-4196-A31B-3CF1C09DE773 Q34775850-2CA157BC-FB9D-4BF4-8890-1C05FCCD0290 Q34791108-9450CC64-79EB-4362-9D5D-FA95DEA7C0B8 Q34984510-DF96E53A-9888-4C39-8C95-1EEFA1EAAF47 Q35005930-BD00EEF6-23E2-4096-9D58-27B78AE47EF4 Q35005940-A8A310FA-F0B3-4768-A05C-1A93ECAC290F Q35041705-090A0F6E-E72D-49DF-9C2D-EA19045BAADE

P2860

Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy.

http://www.wikidata.org/entity/Q37116373

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 26 June 2001

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Altered peptide ligand vaccina ...... cells for tumor immunotherapy.

@en

Altered peptide ligand vaccina ...... cells for tumor immunotherapy.

@nl

type

label

Altered peptide ligand vaccina ...... cells for tumor immunotherapy.

@en

Altered peptide ligand vaccina ...... cells for tumor immunotherapy.

@nl

prefLabel

Altered peptide ligand vaccina ...... cells for tumor immunotherapy.

@en

Altered peptide ligand vaccina ...... cells for tumor immunotherapy.

@nl

P1433

Q37116373-B65304EA-2CE5-42FB-8F6B-1C67FFBB2F06

P1476

Q37116373-59B51020-079E-43DB-83F0-38A9069E259B

P2093

Q37116373-1CFA2C96-7EF7-48E2-ADE7-E73B0BBCD9E3

Q37116373-28D34519-C137-4AFD-9820-7F9CA0CDB737

Q37116373-2F5835B6-43C2-4B68-A043-7DD8295F196A

Q37116373-33EFA69D-72A6-449A-ABFD-2FF0D1954BDC

Q37116373-5AE2F407-EE51-44C4-A419-96091AF67621

Q37116373-9614AFBC-5B06-4B94-91D8-A81A762C897F

Q37116373-C2A8894B-C7F4-4153-9E04-E63AC1EEFF26

Q37116373-DED6021F-D9A0-4491-ADE8-A17B72FF7EC4

P2860

Q37116373-237D624B-AFC7-42FB-9892-61DDBB06F5B7

Q37116373-2DAF8EA4-D57E-4E22-97D0-08B92740626F

Q37116373-43DF1FD5-243D-44F3-BDC3-96708F208CAD

Q37116373-44D2859E-5C78-42C3-898F-31D9CA27BE62

Q37116373-4D630487-99EA-47EA-B357-31A91E7774C3

Q37116373-56A77481-866E-438C-8688-F807C7975AEE

Q37116373-5D2F0824-97D1-468F-BF1D-454C1B398060

Q37116373-5D9C5C0C-796E-4033-9ADB-CAB0AA353E91

Q37116373-608D1CA7-018F-47E4-AEEE-E0848488E2EC

Q37116373-6585DAC0-724E-4EEC-95BC-D4EA10725D03

P304

Q37116373-C668AF19-80CF-49DC-AD21-BE84244D38D2

P31

Q37116373-5DE54140-C344-496D-A230-762BD0E4E0A5

P356

Q37116373-3898D95B-9D3B-4F1F-86FF-AB2FC46BF9EF

P407

Q37116373-F5CD9C04-AA30-451C-9D60-CA1E8D118D58

P433

Q37116373-345D8747-1BD4-48DC-B194-62FE64126E86

P478

Q37116373-E6541AD7-9A76-4C95-810C-304E72DFB8C3

P577

Q37116373-DF989141-AD06-4DC6-838C-CBB8AE9B3624

P5875

Q37116373-AEE404D5-EDF9-4B39-BE9F-67F5C09310E4

P698

Q37116373-884D415C-9EEF-4701-B207-29BDC49D0710

P921

Q37116373-C8D9971D-2ABF-42A6-8594-32290F68FBB4

P932

Q37116373-E497D800-47F2-4AC5-906C-A662EF09B7B0

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Altered peptide ligand vaccina ...... cells for tumor immunotherapy.

@en

P2093

A Rivas

http://www.w3.org/2001/XMLSchema#string

A Yuen

http://www.w3.org/2001/XMLSchema#string

C Benike

http://www.w3.org/2001/XMLSchema#string

E G Engleman

http://www.w3.org/2001/XMLSchema#string

G A Fisher

http://www.w3.org/2001/XMLSchema#string

L Fong

http://www.w3.org/2001/XMLSchema#string

M M Davis

http://www.w3.org/2001/XMLSchema#string

Y Hou

http://www.w3.org/2001/XMLSchema#string

P2860

The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues

Two subsets of memory T lymphocytes with distinct homing potentials and effector functions

Phenotypic analysis of antigen-specific T lymphocytes

Immunobiology of dendritic cells

Positive selection of thymocytes.

Dendritic cells in cancer immunotherapy.

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.

Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified.

Agonist peptide from a cytotoxic t-lymphocyte epitope of human carcinoembryonic antigen stimulates production of tc1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide.

Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.

P304

8809-8814

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.141226398

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

98

http://www.w3.org/2001/XMLSchema#string

P577

2001-06-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11912449

http://www.w3.org/2001/XMLSchema#string

P698

11427731

http://www.w3.org/2001/XMLSchema#string

P921

P932

37517

http://www.w3.org/2001/XMLSchema#string